GenSight Biologics S A : CORPORATE PRESENTATION – OCTOBER 2023

This document contains forward-looking statements and estimates made by the GenSight Biologics S.A. (the "Company"), including with respect to the anticipated future performance of the Company, its subsidiaries and affiliates, and the market in which they operate. They include all matters that are not historical facts. These forward-looking statements can be identified by the use of

forward-looking terminology including the terms "developments," "estimates," "expects," "intends," "may," "milestones," "potential," "value," "time to market," "targeting," "on track," "planned," "will," "move to," or other variations or comparable terminology, or by discussions of strategy and funding, as well as the Company's, its subsidiaries' and affiliates' technology, and

are based on financial and non-financial information, including projections as to the future regulatory situation and other information and assumptions. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may

depend upon factors that are beyond the Company's control. Therefore, actual results, the financial condition, performance or achievements of the Company, its subsidiaries and affiliates or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Forward-looking statements, forecasts and estimates only speak as of the date of this forward-looking statement, and no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. The Company, its subsidiaries and affiliates disclaim any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the

Company's expectations with regard thereto, or any events,

or changes in conditions or circumstances on which any such statement, forecast or estimate is based.

This document is proprietary communication from GenSight Biologics S.A.

1

2

3

4

5

Late-stage Biotech

company

Seasoned

management team / Solid investor base

LUMEVOQ®

Strong clinical data in

LHON

LUMEVOQ®

Defining registration

pathway

Cutting edge optogenetics in Retinitis Pigmentosa

Public company founded in 2012 dedicated to developing and commercializing gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system.

Euronext Paris Listed SIGHT

Management team with strong and highly relevant Biotech experience in R&D and commercialization

Solid investor base of Healthcare specialist investors, including EU and US based investors.

LUMEVOQ® completed 3 Phase III studies in Leber Hereditary Optic Neuropathy (ND4 LHON), a rare and highly debilitating genetic ophthalmic disease leading to sudden loss of central vision and affecting c. 1,200 - 1,500 new patients / year in Europe and the US. Overall design of new Phase III RECOVER endorsed by EMA.

Available in France through paid Early Access at €700,000 for a bilateral injection (currently paused pending product availability in Q1 2024). Manufacturing issues successfully remediated.

Ongoing discussion with EMA, UK MHRA and US FDA to confirm registration pathway

GS030 outstanding early findings reporting blind patients to precisely identify objects (published in Nature Medicine in May 21) ; 1-yr data from PIONEER Phase I/II Clinical Trial reported in Feb 2023

Extension cohort currently being recruited, expected to be completed by year end 2023

Bernard Gilly

Chief Executive Officer

PIXIUM VISION (Since 2011)

FOVEA PHARMA (2005-2009)

SOFINNOVA PARTNERS (2000-2005)

TRANSGENE (1992-2000)

Ph.D. in biology and bio-economics

Scott Jeffers

Chief Technical Officer

REDPIN THERAPEUTICS (2021-2022)

UNIQURE (2019-2021)

SELECTA BIOSCIENCES (2018-2019)

BRAMMER BIO (2015-2018)

Ph.D. in virology

4 October 2023 - Non-Confidential

Thomas Gidoin

Chief Financial Officer

DBV TECHNOLOGIES(2012-2015) IPSEN (2008-2011)

ERNST & YOUNG (2007-2008)

Magali Taiel

Chief Medical Officer

ProQR THERAPEUTICS (2016-2018)

ELI LILLY (2004-2016)

PFIZER (2001-2004)

SERVIER (1999-2001)

M.D., Board-certified ophthalmologist

Philippe Motté

SVP, Regulatory & Quality

GENFIT (2020-2022)

MEDDAY (2019-2020)

ABBVIE (2013-2018)

IPSEN (2004-2013)

ROCHE (1998-2004)

GSK (1991-1998)

SANOFI (1989-1991)

Pharm.D. & Ph.D. in human biology

MTS Platform

LHON ND4 (EU)

EMA Orphan Drug Designation

LHON ND4 (US)

FDA Orphan Drug Designation

GS011 LHON ND1

New Undisclosed

Optogenetics

~ 250 new patients per year

~ 100 new patients per year

~ 1,500 new patients per year

* Following the withdrawal of the EMA application in April 2023, GenSight is assessing next steps with the EMA

GS030

GS030